 | • レポートコード：MRC2108A125 • 出版社/出版日：Mordor Intelligence / 2021年7月26日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、診断用酵素の世界市場規模が、2021年から2026年の間に年平均6.2％成長すると予測しています。本調査レポートは、世界の診断用酵素市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（ポリメラーゼ＆ヌクレアーゼ、カルボヒドラーゼ、プロテアーゼ、オキシダーゼ、その他）分析、用途別（臨床化学、分子診断、その他）分析、エンドユーザー別（病院、臨床研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・診断用酵素の世界市場規模：種類別（ポリメラーゼ＆ヌクレアーゼ、カルボヒドラーゼ、プロテアーゼ、オキシダーゼ、その他） ・診断用酵素の世界市場規模：用途別（臨床化学、分子診断、その他） ・診断用酵素の世界市場規模：エンドユーザー別（病院、臨床研究所、その他） ・診断用酵素の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Sanofi SA、F. Hoffmann-La Roche Ltd.、Codexis, Inc.、Amano Enzymes Inc.、Aldevron、American Laboratories, Inc.、Biocatalysts Ltd.、Kaneka Eurogentec、Thermo Fisher Scientific、EKF Diagnostics） ・市場機会/将来の見通し |
The diagnostics enzyme market is expected to register a CAGR of 6.2% during the forecast period of 2021-2026.
While COVID-19 had severely impacted the pharmaceutical and biotechnology sectors for a brief time due to the lockdown scenario but eventually it had helped them as it provided them an opportunity to make and launch new drugs or vaccines against COVID-19. Many companies are developing COVID-19 vaccines and their adjuvants in a very short time by putting every resource available on their disposable as an imminent threat of COVID-19 looms over the world. The same goes for the diagnostics enzyme manufacturing companies as they are now busy with several things related to COVID-19, such as COVID-19 diagnostic kits, identification and analysis of the spike proteins, development of new enzyme-based treatment methods, and many other things. For example, after the COVID-19 outbreak, researchers identified SARS-CoV-2 virus binds to an enzyme present in the human body called angiotensin-converting enzyme 2 which normally regulates blood pressure in the human body (PubMed, July 2020) and now researchers are working on this breakthrough to get the cure for COVID-19. Apart from this, other studies are also going on.
For the diagnostics enzyme market, the major growth factor is the increasing adoption of enzyme-based diagnostic tests couple with the innovations in diagnostics technologies. The new innovations and development in biotechnology domain, increasing chronic and infectious diseases and huge funding in research and development for the same. Over the years Biotechnology sector came out as a one of the fastest growing market because of new research and development. For example, clustered regularly interspaced short palindromic repeats (CRISPR) technology which had opened new gates for the recombinant DNA technology in medical, pharmaceutical, and other sectors. Other factors responsible for the growth of diagnostic enzyme market are rise in infectious and other chronic diseases all over the world, increasing interest of companies towards the enzyme because of its dynamic functions, and growing geriatric population worldwide. As per the United Nation’s World Ageing Highlight of 2020, there were about 727 million people aged 65 and older , living all over the world and this number is expected to reach 1.5 billion people by 2050, which will also complement the growth of the diagnostics enzyme market.
The major restraining factor for the growth of diagnostic enzyme market is high sensitivity of enzymes towards pH and temperature. Enzymes are kind of protein which requires an optimum condition to be stable and perform its function, in two factors are very important in it, optimum pH and temperature. A slight difference in these two factors can denature the enzyme leading to no or very poor result from the diagnostic kit and as in most of the countries except developed countries, the logistics and storage conditions are as not good as it should be to maintain the optimum condition for the enzyme. Another factor is cost of the enzyme which is usually very high due to the high cost associated with the production and isolation of the enzyme.
Key Market Trends
Nuclease Enzymes are Expected to Dominate the Diagnostic Enzyme Market During the Forecast Period
The nuclease enzymes are two of the most necessary and crucial enzymes which have a wide array of applications in pharmaceuticals, research, and development in biotechnology, clinical diagnostics, and others. Therefore, these enzymes are very important enzymes for all pharmaceutical and biotechnology companies, and molecular biology research institutes.
The use of nuclease enzymes is expected to increase manifolds during the forecast period due to new ongoing research in DNA sequencing and DNA amplification, RNA sequencing and RNA amplification, and the development of nucleases-based diagnostic kits for the detection of infectious diseases and some other applications. For example, in May 2020, Co-Diagnostics successfully tests a nuclease-based testing kit to identify COVID-19 in cancer cells, the kit is known as Logix Smart. Similarly, In August 2020, Sherlock Biosciences entered a collaboration with Dartmouth-Hitchcock Health (D-HH) to launch a clinical study of the Sherlock CRISPR nuclease-based SARS-CoV-2 kit for the detection of the novel coronavirus that causes COVID-19. Also, the rising demand and acceptance of personal and precision medicine for various chronic and genetic diseases is expected to increase the demand for nuclease enzymes in the forecast period.
North America is Expected to Dominate the Market of Diagnostics Enzyme During the Forecast Period
The North American region includes the United States, Canada, and Mexico. Due to huge funding in the research and development by the government as well as private players and the presence of key market players in North America, there will be significant growth in North America in the studied market and is expected to occupy a major share in the diagnostics enzyme market during the forecast period.
In North America, the major growth is expected to be observed in the United States because it is more technologically advanced than the rest of the world and, the research and development spending of the United States is very high. According to the National Center for Science and Engineering Statistics in 2018, the total research and development cost of the United States was about USD 606.1 billion, and based on performance reports, it was estimated that in 2019 the total capital investment in research and development will be around USD 656 billion. The other reason for the major share of the United States is the presence of key market players who are innovating and launching new products, world-class research institutes run by some of the most prominent scientists (Nobel laureates too), technologically advanced biotechnology companies, and awareness among the public. For instance, in January 2021, Thermo Fisher Scientific announced the acquisition of an molecular diagnostics company known as Mesa Biotech, Inc based in San Diego.
After the United States, Canada will occupy the second-largest share in the diagnostics enzyme market in North America followed by Mexico. Canada is following the path of United States and investing heavily on research and development in pharmaceutical and biotechnology sector apart from improving its health infrastructure and awareness among public.
Competitive Landscape
The diagnostics enzyme market will be highly competitive due to the presence of some huge multinational enzyme companies and because of the new biotechnology companies in the market and their advanced and very critical research and innovations. Some of the major market players of the diagnostics enzyme market are – Sanofi Genzyme, F. Hoffmann-La Roche Ltd., Codexis Inc., Aldevron, Amano Enzymes, Biocatalysts Ltd., Kaneka Eurogentec, etc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Adoption of Enzyme Based Diagnostic Tests Coupled with the Innovations in Diagnostic Technologies
4.2.2 Growing Burden of Chronic and Infectious Diseases
4.3 Market Restraints
4.3.1 High Sensitivity of Enzymes Towards pH and Temperature
4.3.2 Production and Isolation Cost of Enzymes
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Polymerases and Nucleases
5.1.2 Carbohydrases
5.1.3 Proteases
5.1.4 Oxidases
5.1.5 Others
5.2 By Application
5.2.1 Clinical Chemistry
5.2.2 Molecular Diagnostics
5.2.3 Others
5.3 By End Users
5.3.1 Hospitals
5.3.2 Clinical Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sanofi SA
6.1.2 F. Hoffmann-La Roche Ltd.
6.1.3 Codexis, Inc.
6.1.4 Amano Enzymes Inc.
6.1.5 Aldevron
6.1.6 American Laboratories, Inc.
6.1.7 Biocatalysts Ltd.
6.1.8 Kaneka Eurogentec
6.1.9 Thermo Fisher Scientific
6.1.10 EKF Diagnostics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS